{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T16:37:19Z","timestamp":1780331839696,"version":"3.54.1"},"reference-count":132,"publisher":"Pharmaceutical Society of Japan","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biological & Pharmaceutical Bulletin","Biol. Pharm. Bull."],"published-print":{"date-parts":[[2013]]},"DOI":"10.1248\/bpb.b13-00369","type":"journal-article","created":{"date-parts":[[2013,8,31]],"date-time":"2013-08-31T23:08:50Z","timestamp":1377990530000},"page":"1381-1390","source":"Crossref","is-referenced-by-count":25,"title":["Functional Alterations of Intestinal P-Glycoprotein under Diabetic Conditions"],"prefix":"10.1248","volume":"36","author":[{"given":"Takuro","family":"Kobori","sequence":"first","affiliation":[{"name":"Department of Clinical Pharmacy, School of Pharmaceutical Sciences, Kobe Gakuin University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinichi","family":"Harada","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, School of Pharmaceutical Sciences, Kobe Gakuin University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuo","family":"Nakamoto","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, School of Pharmaceutical Sciences, Kobe Gakuin University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shogo","family":"Tokuyama","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, School of Pharmaceutical Sciences, Kobe Gakuin University"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"163","reference":[{"key":"1","unstructured":"1) Lagas JS, van Waterschoot RA, Sparidans RW, Wagenaar E, Beijnen JH, Schinkel AH. Breast cancer resistance protein and P-glycoprotein limit sorafenib brain accumulation. Mol. Cancer Ther.<\/i>, 9, 319\u2013326 (2010)."},{"key":"2","unstructured":"2) Kimura Y, Aoki J, Kohno M, Ooka H, Tsuruo T, Nakanishi O. P-Glycoprotein inhibition by the multidrug resistance-reversing agent MS-209 enhances bioavailability and antitumor efficacy of orally administered paclitaxel. Cancer Chemother. Pharmacol.<\/i>, 49, 322\u2013328 (2002)."},{"key":"3","unstructured":"3) Hsiu SL, Hou YC, Wang YH, Tsao CW, Su SF, Chao PD. Quercetin significantly decreased cyclosporin oral bioavailability in pigs and rats. Life Sci.<\/i>, 72, 227\u2013235 (2002)."},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Marchetti S, Mazzanti R, Beijnen JH, Schellens JH. Concise review: Clinical relevance of drug drug and herb drug interactions mediated by the ABC transporter ABCB1 (MDR1, P-glycoprotein). Oncologist<\/i>, 12, 927\u2013941 (2007).","DOI":"10.1634\/theoncologist.12-8-927"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Lin JH. Drug\u2013drug interaction mediated by inhibition and induction of P-glycoprotein. Adv. Drug Deliv. Rev.<\/i>, 55, 53\u201381 (2003).","DOI":"10.1016\/S0169-409X(02)00171-0"},{"key":"6","unstructured":"6) Mizuno N, Sugiyama Y. Drug transporters: their role and importance in the selection and development of new drugs. Drug Metab. Pharmacokinet.<\/i>, 17, 93\u2013108 (2002)."},{"key":"7","unstructured":"7) Rees DC, Johnson E, Lewinson O. ABC transporters: the power to change. Nat. Rev. Mol. Cell Biol.<\/i>, 10, 218\u2013227 (2009)."},{"key":"8","unstructured":"8) Brady JM, Cherrington NJ, Hartley DP, Buist SC, Li N, Klaassen CD. Tissue distribution and chemical induction of multiple drug resistance genes in rats. Drug Metab. Dispos.<\/i>, 30, 838\u2013844 (2002)."},{"key":"9","unstructured":"9) Hamabe W, Maeda T, Kiguchi N, Yamamoto C, Tokuyama S, Kishioka S. Negative relationship between morphine analgesia and P-glycoprotein expression levels in the brain. J. Pharmacol. Sci.<\/i>, 105, 353\u2013360 (2007)."},{"key":"10","unstructured":"10) Xie R, Hammarlund\u2013Udenaes M, de Boer AG, de Lange EC. The role of P-glycoprotein in blood\u2013brain barrier transport of morphine: transcortical microdialysis studies in mdr1a (\u2212\/\u2212) and mdr1a (+\/+) mice. Br. J. Pharmacol.<\/i>, 128, 563\u2013568 (1999)."},{"key":"11","unstructured":"11) Letrent SP, Pollack GM, Brouwer KR, Brouwer KL. Effects of a potent and specific P-glycoprotein inhibitor on the blood\u2013brain barrier distribution and antinociceptive effect of morphine in the rat. Drug Metab. Dispos.<\/i>, 27, 827\u2013834 (1999)."},{"key":"12","unstructured":"12) Mayer U, Wagenaar E, Beijnen JH, Smit JW, Meijer DK, van Asperen J, Borst P, Schinkel AH. Substantial excretion of digoxin via<\/i> the intestinal mucosa and prevention of long-term digoxin accumulation in the brain by the mdr1a P-glycoprotein. Br. J. Pharmacol.<\/i>, 119, 1038\u20131044 (1996)."},{"key":"13","unstructured":"13) Ishikawa T, Hirano H, Onishi Y, Sakurai A, Tarui S. Functional evaluation of ABCB1 (P-glycoprotein) polymorphisms: high-speed screening and structure\u2013activity relationship analyses. Drug Metab. Pharmacokinet.<\/i>, 19, 1\u201314 (2004)."},{"key":"14","unstructured":"14) Ikemura K, Urano K, Matsuda H, Mizutani H, Iwamoto T, Okuda M. Decreased oral absorption of cyclosporine A after liver ischemia-reperfusion injury in rats: the contribution of CYP3A and P-glycoprotein to the first-pass metabolism in intestinal epithelial cells. J. Pharmacol. Exp. Ther.<\/i>, 328, 249\u2013255 (2009)."},{"key":"15","unstructured":"15) Marzolini C, Paus E, Buclin T, Kim RB. Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance. Clin. Pharmacol. Ther.<\/i>, 75, 13\u201333 (2004)."},{"key":"16","unstructured":"16) Thuerauf N, Fromm MF. The role of the transporter P-glycoprotein for disposition and effects of centrally acting drugs and for the pathogenesis of CNS diseases. Eur. Arch. Psychiatry Clin. Neurosci.<\/i>, 256, 281\u2013286 (2006)."},{"key":"17","unstructured":"17) Zong J, Pollack GM. Morphine antinociception is enhanced in mdr1a gene-deficient mice. Pharm. Res.<\/i>, 17, 749\u2013753 (2000)."},{"key":"18","unstructured":"18) Holmstock N, Mols R, Annaert P, Augustijns P. In situ<\/i> intestinal perfusion in knockout mice demonstrates inhibition of intestinal P-glycoprotein by ritonavir causing increased darunavir absorption. Drug Metab. Dispos.<\/i>, 38, 1407\u20131410 (2010)."},{"key":"19","unstructured":"19) Suzuki H, Sugiyama Y. Role of metabolic enzymes and efflux transporters in the absorption of drugs from the small intestine. Eur. J. Pharm. Sci.<\/i>, 12, 3\u201312 (2000)."},{"key":"20","unstructured":"20) Marchetti S, de Vries NA, Buckle T, Bolijn MJ, van Eijndhoven MA, Beijnen JH, Mazzanti R, van Tellingen O, Schellens JH. Effect of the ATP-binding cassette drug transporters ABCB1, ABCG2, and ABCC2 on erlotinib hydrochloride (Tarceva) disposition in in vitro<\/i> and in vivo<\/i> pharmacokinetic studies employing Bcrp1\u2212\/\u2212\/Mdr1a\/1b\u2212\/\u2212 (triple-knockout) and wild-type mice. Mol. Cancer Ther.<\/i>, 7, 2280\u20132287 (2008)."},{"key":"21","unstructured":"21) Masuda S, Uemoto S, Hashida T, Inomata Y, Tanaka K, Inui K. Effect of intestinal P-glycoprotein on daily tacrolimus trough level in a living-donor small bowel recipient. Clin. Pharmacol. Ther.<\/i>, 68, 98\u2013103 (2000)."},{"key":"22","unstructured":"22) Kharasch ED, Hoffer C, Whittington D, Sheffels P. Role of P-glycoprotein in the intestinal absorption and clinical effects of morphine. Clin. Pharmacol. Ther.<\/i>, 74, 543\u2013554 (2003)."},{"key":"23","unstructured":"23) Collett A, Tanianis-Hughes J, Hallifax D, Warhurst G. Predicting P-glycoprotein effects on oral absorption: correlation of transport in Caco-2 with drug pharmacokinetics in wild-type and mdr1a(\u2212\/\u2212) mice in vivo.<\/i> Pharm. Res.<\/i>, 21, 819\u2013826 (2004)."},{"key":"24","unstructured":"24) Letrent SP, Pollack GM, Brouwer KR, Brouwer KL. Effect of GF120918, a potent P-glycoprotein inhibitor, on morphine pharmacokinetics and pharmacodynamics in the rat. Pharm. Res.<\/i>, 15, 599\u2013605 (1998)."},{"key":"25","unstructured":"25) Fujita-Hamabe W, Nishida M, Nawa A, Kobori T, Nakamoto K, Kishioka S, Tokuyama S. Etoposide modulates the effects of oral morphine analgesia by targeting the intestinal P-glycoprotein. J. Pharm. Pharmacol.<\/i>, 64, 496\u2013504 (2012)."},{"key":"26","unstructured":"26) Okura T, Morita Y, Ito Y, Kagawa Y, Yamada S. Effects of quinidine on antinociception and pharmacokinetics of morphine in rats. J. Pharm. Pharmacol.<\/i>, 61, 593\u2013597 (2009)."},{"key":"27","unstructured":"27) Ghanem CI, Gomez PC, Arana MC, Perassolo M, Delli Carpini G, Luquita MG, Veggi LM, Catania VA, Bengochea LA, Mottino AD. Induction of rat intestinal P-glycoprotein by spironolactone and its effect on absorption of orally administered digoxin. J. Pharmacol. Exp. Ther.<\/i>, 318, 1146\u20131152 (2006)."},{"key":"28","unstructured":"28) Greiner B, Eichelbaum M, Fritz P, Kreichgauer HP, von Richter O, Zundler J, Kroemer HK. The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin. J. Clin. Invest.<\/i>, 104, 147\u2013153 (1999)."},{"key":"29","unstructured":"29) Westphal K, Weinbrenner A, Zschiesche M, Franke G, Knoke M, Oertel R, Fritz P, von Richter O, Warzok R, Hachenberg T, Kauffmann HM, Schrenk D, Terhaag B, Kroemer HK, Siegmund W. Induction of P-glycoprotein by rifampin increases intestinal secretion of talinolol in human beings: a new type of drug\/drug interaction. Clin. Pharmacol. Ther.<\/i>, 68, 345\u2013355 (2000)."},{"key":"30","unstructured":"30) Westphal K, Weinbrenner A, Giessmann T, Stuhr M, Franke G, Zschiesche M, Oertel R, Terhaag B, Kroemer HK, Siegmund W. Oral bioavailability of digoxin is enhanced by talinolol: evidence for involvement of intestinal P-glycoprotein. Clin. Pharmacol. Ther.<\/i>, 68, 6\u201312 (2000)."},{"key":"31","unstructured":"31) Hamman MA, Bruce MA, Haehner-Daniels BD, Hall SD. The effect of rifampin administration on the disposition of fexofenadine. Clin. Pharmacol. Ther.<\/i>, 69, 114\u2013121 (2001)."},{"key":"32","unstructured":"32) Zhang Y, Jiang XH, Hu YQ, Li ZR, Su L, Wang ZG, Ma G. MDR1 genotypes do not influence the absorption of a single oral dose of 600\u2009mg valacyclovir in healthy Chinese Han ethnic males. Br. J. Clin. Pharmacol.<\/i>, 66, 247\u2013254 (2008)."},{"key":"33","unstructured":"33) Hoffmeyer S, Burk O, von Richter O, Arnold HP, Brockmoller J, Johne A, Cascorbi I, Gerloff T, Roots I, Eichelbaum M, Brinkmann U. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo.<\/i> Proc. Natl. Acad. Sci. U.S.A.<\/i>, 97, 3473\u20133478 (2000)."},{"key":"34","unstructured":"34) Mendoza JL, Urcelay E, Lana R, Martin MC, Lopez N, Guijarro LG, Mayol JA, Taxonera C, de la Concha EG, Pena AS, Diaz-Rubio M. MDR1 polymorphisms and response to azathioprine therapy in patients with Crohn\u2019s disease. Inflamm. Bowel Dis.<\/i>, 13, 585\u2013590 (2007)."},{"key":"35","unstructured":"35) Jiang ZP, Wang YR, Xu P, Liu RR, Zhao XL, Chen FP. Meta-analysis of the effect of MDR1 C3435T polymorphism on cyclosporine pharmacokinetics. Basic Clin. Pharmacol. Toxicol.<\/i>, 103, 433\u2013444 (2008)."},{"key":"36","unstructured":"36) Lown KS, Mayo RR, Leichtman AB, Hsiao HL, Turgeon DK, Schmiedlin-Ren P, Brown MB, Guo W, Rossi SJ, Benet LZ, Watkins PB. Role of intestinal P-glycoprotein (mdr1) in interpatient variation in the oral bioavailability of cyclosporine. Clin. Pharmacol. Ther.<\/i>, 62, 248\u2013260 (1997)."},{"key":"37","unstructured":"37) Okura T, Ozawa T, Ito Y, Kimura M, Kagawa Y, Yamada S. Enhancement by grapefruit juice of morphine antinociception. Biol. Pharm. Bull.<\/i>, 31, 2338\u20132341 (2008)."},{"key":"38","unstructured":"38) Pal D, Mitra AK. MDR- and CYP3A4-mediated drug\u2013herbal interactions. Life Sci.<\/i>, 78, 2131\u20132145 (2006)."},{"key":"39","unstructured":"39) Wang EJ, Casciano CN, Clement RP, Johnson WW. Inhibition of P-glycoprotein transport function by grapefruit juice psoralen. Pharm. Res.<\/i>, 18, 432\u2013438 (2001)."},{"key":"40","unstructured":"40) Kobori T, Kobayashi M, Harada S, Nakamoto K, Fujita-Hamabe W, Tokuyama S. RhoA affects oral morphine analgesia depending on functional variation in intestinal P-glycoprotein induced by repeated etoposide treatment. Eur. J. Pharm. Sci.<\/i>, 47, 934\u2013940 (2012)."},{"key":"41","unstructured":"41) Demeule M, Jodoin J, Beaulieu E, Brossard M, Beliveau R. Dexamethasone modulation of multidrug transporters in normal tissues. FEBS Lett.<\/i>, 442, 208\u2013214 (1999)."},{"key":"42","doi-asserted-by":"crossref","unstructured":"42) Jette L, Beaulieu E, Leclerc JM, Beliveau R. Cyclosporin A treatment induces overexpression of P-glycoprotein in the kidney and other tissues. Am. J. Physiol.<\/i>, 270, F756\u2013F765 (1996).","DOI":"10.1152\/ajprenal.1996.270.5.F756"},{"key":"43","unstructured":"43) Ronaldson PT, Ashraf T, Bendayan R. Regulation of multidrug resistance protein 1 by tumor necrosis factor alpha in cultured glial cells: involvement of nuclear factor-kappaB and c-Jun N-terminal kinase signaling pathways. Mol. Pharmacol.<\/i>, 77, 644\u2013659 (2010)."},{"key":"44","unstructured":"44) Garcia MG, Alaniz LD, Cordo Russo RI, Alvarez E, Hajos SE. PI3K\/Akt inhibition modulates multidrug resistance and activates NF-kappaB in murine lymphoma cell lines. Leuk. Res.<\/i>, 33, 288\u2013296 (2009)."},{"key":"45","doi-asserted-by":"crossref","unstructured":"45) Tishler DM, Weinberg KI, Hinton DR, Barbaro N, Annett GM, Raffel C. MDR1 gene expression in brain of patients with medically intractable epilepsy. Epilepsia<\/i>, 36, 1\u20136 (1995).","DOI":"10.1111\/j.1528-1157.1995.tb01657.x"},{"key":"46","unstructured":"46) Yu N, Di Q, Liu H, Hu Y, Jiang Y, Yan YK, Zhang YF, Zhang YD. Nuclear factor-kappa B activity regulates brain expression of P-glycoprotein in the kainic acid-induced seizure rats. Mediators Inflamm.<\/i>, 2011, 670613 (2011)."},{"key":"47","unstructured":"47) Maeng HJ, Kim MH, Jin HE, Shin SM, Tsuruo T, Kim SG, Kim DD, Shim CK, Chung SJ. Functional induction of P-glycoprotein in the blood\u2013brain barrier of streptozotocin-induced diabetic rats: evidence for the involvement of nuclear factor-kappaB, a nitrosative stress-sensitive transcription factor, in the regulation. Drug Metab. Dispos.<\/i>, 35, 1996\u20132005 (2007)."},{"key":"48","unstructured":"48) Whiting DR, Guariguata L, Weil C, Shaw J. IDF diabetes atlas: global estimates of the prevalence of diabetes for 2011 and 2030. Diabetes Res. Clin. Pract.<\/i>, 94, 311\u2013321 (2011)."},{"key":"49","doi-asserted-by":"crossref","unstructured":"49) Danaei G, Finucane MM, Lu Y, Singh GM, Cowan MJ, Paciorek CJ, Lin JK, Farzadfar F, Khang YH, Stevens GA, Rao M, Ali MK, Riley LM, Robinson CA, Ezzati M, Global Burden of Metabolic Risk Factors of Chronic Diseases Collaborating Group (Blood Glucose). National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2.7 million participants. Lancet<\/i>, 378, 31\u201340 (2011).","DOI":"10.1016\/S0140-6736(11)60679-X"},{"key":"50","unstructured":"50) Kameyama N, Arisawa S, Ueyama J, Kagota S, Shinozuka K, Hattori A, Tatsumi Y, Hayashi H, Takagi K, Wakusawa S. Increase in P-glycoprotein accompanied by activation of protein kinase Calpha and NF-kappaB p65 in the livers of rats with streptozotocin-induced diabetes. Biochim. Biophys. Acta<\/i>, 1782, 355\u2013360 (2008)."},{"key":"51","unstructured":"51) Yeh SY, Pan HJ, Lin CC, Kao YH, Chen YH, Lin CJ. Hyperglycemia induced down-regulation of renal P-glycoprotein expression. Eur. J. Pharmacol.<\/i>, 690, 42\u201350 (2012)."},{"key":"52","unstructured":"52) Tramonti G, Xie P, Wallner EI, Danesh FR, Kanwar YS. Expression and functional characteristics of tubular transporters: P-glycoprotein, PEPT1, and PEPT2 in renal mass reduction and diabetes. Am. J. Physiol. Renal Physiol.<\/i>, 291, F972\u2013F980 (2006)."},{"key":"53","unstructured":"53) Liu H, Xu X, Yang Z, Deng Y, Liu X, Xie L. Impaired function and expression of P-glycoprotein in blood\u2013brain barrier of streptozotocin-induced diabetic rats. Brain Res.<\/i>, 1123, 245\u2013252 (2006)."},{"key":"54","doi-asserted-by":"crossref","unstructured":"54) van Waarde WM, Verkade HJ, Wolters H, Havinga R, Baller J, Bloks V, Muller M, Sauer PJ, Kuipers F. Differential effects of streptozotocin-induced diabetes on expression of hepatic ABC-transporters in rats. Gastroenterology<\/i>, 122, 1842\u20131852 (2002).","DOI":"10.1053\/gast.2002.33582"},{"key":"55","unstructured":"55) Cygalova LH, Hofman J, Ceckova M, Staud F. Transplacental pharmacokinetics of glyburide, rhodamine 123, and BODIPY FL prazosin: effect of drug efflux transporters and lipid solubility. J. Pharmacol. Exp. Ther.<\/i>, 331, 1118\u20131125 (2009)."},{"key":"56","unstructured":"56) Golstein PE, Boom A, van Geffel J, Jacobs P, Masereel B, Beauwens R. P-glycoprotein inhibition by glibenclamide and related compounds. Pflugers Arch.<\/i>, 437, 652\u2013660 (1999)."},{"key":"57","unstructured":"57) Lilja JJ, Niemi M, Fredrikson H, Neuvonen PJ. Effects of clarithromycin and grapefruit juice on the pharmacokinetics of glibenclamide. Br. J. Clin. Pharmacol.<\/i>, 63, 732\u2013740 (2007)."},{"key":"58","doi-asserted-by":"crossref","unstructured":") Hemauer SJ, Patrikeeva SL, Nanovskaya TN, Hankins GD, Ahmed MS. Role of human placental apical membrane transporters in the efflux of glyburide, rosiglitazone, and metformin. Am. J. Obstet. Gynecol.<\/i>, 202, 383.e1\u2013387.e7 (2010).","DOI":"10.1016\/j.ajog.2010.01.035"},{"key":"59","unstructured":"59) Choi YH, Lee DC, Lee I, Lee MG. Changes in metformin pharmacokinetics after intravenous and oral administration to rats with short-term and long-term diabetes induced by streptozotocin. J. Pharm. Sci.<\/i>, 97, 5363\u20135375 (2008)."},{"key":"60","unstructured":"60) Li C, Choi DH, Choi JS. Effects of efonidipine on the pharmacokinetics and pharmacodynamics of repaglinide: possible role of CYP3A4 and P-glycoprotein inhibition by efonidipine. J. Pharmacokinet. Pharmacodyn.<\/i>, 39, 99\u2013108 (2012)."},{"key":"61","unstructured":"61) Kajosaari LI, Niemi M, Neuvonen M, Laitila J, Neuvonen PJ, Backman JT. Cyclosporine markedly raises the plasma concentrations of repaglinide. Clin. Pharmacol. Ther.<\/i>, 78, 388\u2013399 (2005)."},{"key":"62","unstructured":"62) Chang C, Bahadduri PM, Polli JE, Swaan PW, Ekins S. Rapid identification of P-glycoprotein substrates and inhibitors. Drug Metab. Dispos.<\/i>, 34, 1976\u20131984 (2006)."},{"key":"63","unstructured":"63) Chu XY, Bleasby K, Yabut J, Cai X, Chan GH, Hafey MJ, Xu S, Bergman AJ, Braun MP, Dean DC, Evers R. Transport of the dipeptidyl peptidase-4 inhibitor sitagliptin by human organic anion transporter 3, organic anion transporting polypeptide 4C1, and multidrug resistance P-glycoprotein. J. Pharmacol. Exp. Ther.<\/i>, 321, 673\u2013683 (2007)."},{"key":"64","unstructured":"64) Krishna R, Bergman A, Larson P, Cote J, Lasseter K, Dilzer S, Wang A, Zeng W, Chen L, Wagner J, Herman G. Effect of a single cyclosporine dose on the single-dose pharmacokinetics of sitagliptin (MK-0431), a dipeptidyl peptidase-4 inhibitor, in healthy male subjects. J. Clin. Pharmacol.<\/i>, 47, 165\u2013174 (2007)."},{"key":"65","doi-asserted-by":"crossref","unstructured":"65) Scheen AJ. Pharmacokinetics of dipeptidylpeptidase-4 inhibitors. Diabetes Obes. Metab.<\/i>, 12, 648\u2013658 (2010).","DOI":"10.1111\/j.1463-1326.2010.01212.x"},{"key":"66","doi-asserted-by":"crossref","unstructured":"66) Scheen AJ. Dipeptidylpeptidase-4 inhibitors (gliptins): focus on drug\u2013drug interactions. Clin. Pharmacokinet.<\/i>, 49, 573\u2013588 (2010).","DOI":"10.2165\/11532980-000000000-00000"},{"key":"67","unstructured":"67) Fuchs H, Runge F, Held HD. Excretion of the dipeptidyl peptidase-4 inhibitor linagliptin in rats is primarily by biliary excretion and P-gp-mediated efflux. Eur. J. Pharm. Sci.<\/i>, 45, 533\u2013538 (2012)."},{"key":"68","unstructured":"68) Nawa A, Fujita Hamabe W, Tokuyama S. Inducible nitric oxide synthase-mediated decrease of intestinal P-glycoprotein expression under streptozotocin-induced diabetic conditions. Life Sci.<\/i>, 86, 402\u2013409 (2010)."},{"key":"69","unstructured":"69) Pandey V, Chaube B, Bhat MK. Hyperglycemia regulates MDR-1, drug accumulation and ROS levels causing increased toxicity of carboplatin and 5-fluorouracil in MCF-7 cells. J. Cell. Biochem.<\/i>, 112, 2942\u20132952 (2011)."},{"key":"70","unstructured":"70) Nawa A, Fujita-Hamabe W, Tokuyama S. Regulatory action of nitric oxide synthase on ileal P-glycoprotein expression under streptozotocin-induced diabetic condition. Biol. Pharm. Bull.<\/i>, 34, 436\u2013438 (2011)."},{"key":"71","unstructured":"71) Zhang LL, Lu L, Jin S, Jing XY, Yao D, Hu N, Liu L, Duan R, Liu XD, Wang GJ, Xie L. Tissue-specific alterations in expression and function of P-glycoprotein in streptozotocin-induced diabetic rats. Acta Pharmacol. Sin.<\/i>, 32, 956\u2013966 (2011)."},{"key":"72","unstructured":"72) Nawa A, Fujita-Hamabe W, Tokuyama S. Altered intestinal P-glycoprotein expression levels in a monosodium glutamate-induced obese mouse model. Life Sci.<\/i>, 89, 834\u2013838 (2011)."},{"key":"73","unstructured":"73) Sugioka N, Haraya K, Fukushima K, Ito Y, Takada K. Effects of obesity induced by high-fat diet on the pharmacokinetics of nelfinavir, a HIV protease inhibitor, in laboratory rats. Biopharm. Drug Dispos.<\/i>, 30, 532\u2013541 (2009)."},{"key":"74","unstructured":"74) Wu KC, Pan HJ, Yin HS, Chen MR, Lu SC, Lin CJ. Change in P-glycoprotein and caveolin protein expression in brain striatum capillaries in New Zealand obese mice with type 2 diabetes. Life Sci.<\/i>, 85, 775\u2013781 (2009)."},{"key":"75","unstructured":"75) Nowicki MT, Aleksunes LM, Sawant SP, Dnyanmote AV, Mehendale HM, Manautou JE. Renal and hepatic transporter expression in type 2 diabetic rats. Drug Metab. Lett.<\/i>, 2, 11\u201317 (2008)."},{"key":"76","unstructured":"76) Shen J, Hughes C, Chao C, Cai J, Bartels C, Gessner T, Subjeck J. Coinduction of glucose-regulated proteins and doxorubicin resistance in Chinese hamster cells. Proc. Natl. Acad. Sci. U.S.A.<\/i>, 84, 3278\u20133282 (1987)."},{"key":"77","unstructured":"77) Ledoux S, Yang R, Friedlander G, Laouari D. Glucose depletion enhances P-glycoprotein expression in hepatoma cells: role of endoplasmic reticulum stress response. Cancer Res.<\/i>, 63, 7284\u20137290 (2003)."},{"key":"78","unstructured":"78) Li Q, Sai Y, Kato Y, Tamai I, Tsuji A. Influence of drugs and nutrients on transporter gene expression levels in Caco-2 and LS180 intestinal epithelial cell lines. Pharm. Res.<\/i>, 20, 1119\u20131124 (2003)."},{"key":"79","unstructured":"79) Parissenti AM, Gannon BR, Villeneuve DJ, Kirwan-rhude AF, Chadderton A, Gluck S. Lack of modulation of MDR1 gene expression by dominant inhibition of cAMP-dependent protein kinase in doxorubicin-resistant MCF-7 breast cancer cells. Int. J. Cancer<\/i>, 82, 893\u2013900 (1999)."},{"key":"80","unstructured":"80) Mbonyi K, van Aelst L, Arguelles JC, Jans AW, Thevelein JM. Glucose-induced hyperaccumulation of cyclic AMP and defective glucose repression in yeast strains with reduced activity of cyclic AMP-dependent protein kinase. Mol. Cell. Biol.<\/i>, 10, 4518\u20134523 (1990)."},{"key":"81","unstructured":"81) Wojtal KA, de Vries E, Hoekstra D, van Ijzendoorn SC. Efficient trafficking of MDR1\/P-glycoprotein to apical canalicular plasma membranes in HepG2 cells requires PKA-RIIalpha anchoring and glucosylceramide. Mol. Biol. Cell<\/i>, 17, 3638\u20133650 (2006)."},{"key":"82","unstructured":"82) Belliard AM, Lacour B, Farinotti R, Leroy C. Effect of tumor necrosis factor-alpha and interferon-gamma on intestinal P-glycoprotein expression, activity, and localization in Caco-2 cells. J. Pharm. Sci.<\/i>, 93, 1524\u20131536 (2004)."},{"key":"83","doi-asserted-by":"crossref","unstructured":"83) Dixit SG, Zingarelli B, Buckley DJ, Buckley AR, Pauletti GM. Nitric oxide mediates increased P-glycoprotein activity in interferon-\u03b3-stimulated human intestinal cells. Am. J. Physiol. Gastrointest. Liver Physiol.<\/i>, 288, G533\u2013G540 (2005).","DOI":"10.1152\/ajpgi.00248.2004"},{"key":"84","unstructured":"84) Kielar ML, John R, Bennett M, Richardson JA, Shelton JM, Chen L, Jeyarajah DR, Zhou XJ, Zhou H, Chiquett B, Nagami GT, Lu CY. Maladaptive role of IL-6 in ischemic acute renal failure. J. Am. Soc. Nephrol.<\/i>, 16, 3315\u20133325 (2005)."},{"key":"85","unstructured":"85) Bauer B, Hartz AM, Miller DS. Tumor necrosis factor alpha and endothelin-1 increase P-glycoprotein expression and transport activity at the blood\u2013brain barrier. Mol. Pharmacol.<\/i>, 71, 667\u2013675 (2007)."},{"key":"86","unstructured":"86) Bauer B, Hartz AM, Pekcec A, Toellner K, Miller DS, Potschka H. Seizure-induced up-regulation of P-glycoprotein at the blood\u2013brain barrier through glutamate and cyclooxygenase-2 signaling. Mol. Pharmacol.<\/i>, 73, 1444\u20131453 (2008)."},{"key":"87","doi-asserted-by":"crossref","unstructured":"87) Bentires-Alj M, Barbu V, Fillet M, Chariot A, Relic B, Jacobs N, Gielen J, Merville MP, Bours V. NF-kappaB transcription factor induces drug resistance through MDR1 expression in cancer cells. Oncogene<\/i>, 22, 90\u201397 (2003).","DOI":"10.1038\/sj.onc.1206056"},{"key":"88","doi-asserted-by":"crossref","unstructured":"88) Kuo MT, Liu Z, Wei Y, Lin-Lee YC, Tatebe S, Mills GB, Unate H. Induction of human MDR1 gene expression by 2-acetylaminofluorene is mediated by effectors of the phosphoinositide 3-kinase pathway that activate NF-kappaB signaling. Oncogene<\/i>, 21, 1945\u20131954 (2002).","DOI":"10.1038\/sj.onc.1205117"},{"key":"89","unstructured":"89) Hartz AM, Bauer B, Block ML, Hong JS, Miller DS. Diesel exhaust particles induce oxidative stress, proinflammatory signaling, and P-glycoprotein up-regulation at the blood\u2013brain barrier. FASEB J.<\/i>, 22, 2723\u20132733 (2008)."},{"key":"90","doi-asserted-by":"crossref","unstructured":"90) Zhang Y, Li C, Sun X, Kuang X, Ruan X. High glucose decreases expression and activity of P-glycoprotein in cultured human retinal pigment epithelium possibly through iNOS induction. PLoS ONE<\/i>, 7, e31631 (2012).","DOI":"10.1371\/journal.pone.0031631"},{"key":"91","unstructured":"91) Powell LA, Warpeha KM, Xu W, Walker B, Trimble ER. High glucose decreases intracellular glutathione concentrations and upregulates inducible nitric oxide synthase gene expression in intestinal epithelial cells. J. Mol. Endocrinol.<\/i>, 33, 797\u2013803 (2004)."},{"key":"92","unstructured":"92) Sugita H, Fujimoto M, Yasukawa T, Shimizu N, Sugita M, Yasuhara S, Martyn JA, Kaneki M. Inducible nitric-oxide synthase and NO donor induce insulin receptor substrate-1 degradation in skeletal muscle cells. J. Biol. Chem.<\/i>, 280, 14203\u201314211 (2005)."},{"key":"93","unstructured":"93) Zhang Z, Wu JY, Hait WN, Yang JM. Regulation of the stability of P-glycoprotein by ubiquitination. Mol. Pharmacol.<\/i>, 66, 395\u2013403 (2004)."},{"key":"94","unstructured":"94) Nawa A, Fujita-Hamabe W, Tokuyama S. Involvement of ubiquitination in the decrease of intestinal P-glycoprotein in a streptozotocin-induced diabetic mouse model. Drug Metab. Pharmacokinet.<\/i>, 27, 548\u2013552 (2012)."},{"key":"95","unstructured":"95) Zhou G, Kuo MT. NF-kappaB-mediated induction of mdr1b expression by insulin in rat hepatoma cells. J. Biol. Chem.<\/i>, 272, 15174\u201315183 (1997)."},{"key":"96","unstructured":"96) Liu H, Liu X, Jia L, Liu Y, Yang H, Wang G, Xie L. Insulin therapy restores impaired function and expression of P-glycoprotein in blood\u2013brain barrier of experimental diabetes. Biochem. Pharmacol.<\/i>, 75, 1649\u20131658 (2008)."},{"key":"97","unstructured":"97) Liu H, Yang H, Wang D, Liu Y, Liu X, Li Y, Xie L, Wang G. Insulin regulates P-glycoprotein in rat brain microvessel endothelial cells via<\/i> an insulin receptor-mediated PKC\/NF-kappaB pathway but not a PI3K\/Akt pathway. Eur. J. Pharmacol.<\/i>, 602, 277\u2013282 (2009)."},{"key":"98","doi-asserted-by":"crossref","unstructured":"98) Pandey SK, He HJ, Chesley A, Juhaszova M, Crow MT, Bernier M. Wortmannin-sensitive pathway is required for insulin-stimulated phosphorylation of inhibitor kappaBalpha. Endocrinology<\/i>, 143, 375\u2013385 (2002).","DOI":"10.1210\/endo.143.2.8619"},{"key":"99","unstructured":"99) Bertrand F, Atfi A, Cadoret A, L\u2019Allemain G, Robin H, Lascols O, Capeau J, Cherqui G. A role for nuclear factor kappaB in the antiapoptotic function of insulin. J. Biol. Chem.<\/i>, 273, 2931\u20132938 (1998)."},{"key":"100","unstructured":"100) Bertrand F, Philippe C, Antoine PJ, Baud L, Groyer A, Capeau J, Cherqui G. Insulin activates nuclear factor kappa B in mammalian cells through a Raf-1-mediated pathway. J. Biol. Chem.<\/i>, 270, 24435\u201324441 (1995)."},{"key":"101","unstructured":"101) Yu K, Wang Y, Wei JR, Ma Q, Wang BQ, Yang CH, Wang MH, Yu D, Li JR. Sodium bisulfite improves rhizome yield and quality in Paris polyphylla<\/i>. Planta Med.<\/i>, 76, 489\u2013494 (2010)."},{"key":"102","doi-asserted-by":"crossref","unstructured":"102) Scheen AJ, Lefebvre PJ. Oral antidiabetic agents. A guide to selection. Drugs<\/i>, 55, 225\u2013236 (1998).","DOI":"10.2165\/00003495-199855020-00004"},{"key":"103","doi-asserted-by":"crossref","unstructured":"103) Scheen AJ. Drug treatment of non-insulin-dependent diabetes mellitus in the 1990s. Achievements and future developments. Drugs<\/i>, 54, 355\u2013368 (1997).","DOI":"10.2165\/00003495-199754030-00001"},{"key":"104","unstructured":"104) Krentz AJ, Bailey CJ. Oral antidiabetic agents: current role in type 2 diabetes mellitus. Drugs<\/i>, 65, 385\u2013411 (2005)."},{"key":"105","doi-asserted-by":"crossref","unstructured":"105) He L, Sabet A, Djedjos S, Miller R, Sun X, Hussain MA, Radovick S, Wondisford FE. Metformin and insulin suppress hepatic gluconeogenesis through phosphorylation of CREB binding protein. Cell<\/i>, 137, 635\u2013646 (2009).","DOI":"10.1016\/j.cell.2009.03.016"},{"key":"106","unstructured":"106) Phielix E, Szendroedi J, Roden M. The role of metformin and thiazolidinediones in the regulation of hepatic glucose metabolism and its clinical impact. Trends Pharmacol. Sci.<\/i>, 32, 607\u2013616 (2011)."},{"key":"107","unstructured":"107) Croxtall JD, Keam SJ. Vildagliptin: a review of its use in the management of type 2 diabetes mellitus. Drugs<\/i>, 68, 2387\u20132409 (2008)."},{"key":"108","unstructured":"108) Rigby SP, Handelsman Y, Lai YL, Abby SL, Tao B, Jones MR. Effects of colesevelam, rosiglitazone, or sitagliptin on glycemic control and lipid profile in patients with type 2 diabetes mellitus inadequately controlled by metformin monotherapy. Endocr. Pract.<\/i>, 16, 53\u201363 (2010)."},{"key":"109","doi-asserted-by":"crossref","unstructured":"109) Kadoglou NP, Tsanikidis H, Kapelouzou A, Vrabas I, Vitta I, Karayannacos PE, Liapis CD, Sailer N. Effects of rosiglitazone and metformin treatment on apelin, visfatin, and ghrelin levels in patients with type 2 diabetes mellitus. Metabolism<\/i>, 59, 373\u2013379 (2010).","DOI":"10.1016\/j.metabol.2009.08.005"},{"key":"110","unstructured":"110) Kadoglou NP, Kapelouzou A, Tsanikidis H, Vitta I, Liapis CD, Sailer N. Effects of rosiglitazone\/metformin fixed-dose combination therapy and metformin monotherapy on serum vaspin, adiponectin and IL-6 levels in drug\u2013na\u00efve patients with type 2 diabetes. Exp. Clin. Endocrinol. Diabetes<\/i>, 119, 63\u201368 (2011)."},{"key":"111","doi-asserted-by":"crossref","unstructured":"111) Kahn SE, Lachin JM, Zinman B, Haffner SM, Aftring RP, Paul G, Kravitz BG, Herman WH, Viberti G, Holman RR, ADOPT Study Group. Effects of rosiglitazone, glyburide, and metformin on beta-cell function and insulin sensitivity in ADOPT. Diabetes<\/i>, 60, 1552\u20131560 (2011).","DOI":"10.2337\/db10-1392"},{"key":"112","doi-asserted-by":"crossref","unstructured":"112) Richter B, Bandeira-Echtler E, Bergerhoff K, Lerch CL. Dipeptidyl peptidase-4 (DPP-4) inhibitors for type 2 diabetes mellitus. Cochrane Database Syst. Rev.<\/i>, CD006739 (2008).","DOI":"10.1002\/14651858.CD006739.pub2"},{"key":"113","unstructured":"113) Idris I, Donnelly R. Dipeptidyl peptidase-IV inhibitors: a major new class of oral antidiabetic drug. Diabetes Obes. Metab.<\/i>, 9, 153\u2013165 (2007)."},{"key":"114","doi-asserted-by":"crossref","unstructured":"114) Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet<\/i>, 368, 1696\u20131705 (2006).","DOI":"10.1016\/S0140-6736(06)69705-5"},{"key":"115","unstructured":"115) Shaw DI, Hall WL, Williams CM. Metabolic syndrome: what is it and what are the implications? Proc. Nutr. Soc.<\/i>, 64, 349\u2013357 (2005)."},{"key":"116","unstructured":"116) Saito I, Iso H, Kokubo Y, Inoue M, Tsugane S. Metabolic syndrome and all-cause and cardiovascular disease mortality: Japan Public Health Center-based Prospective (JPHC) Study. Circ. J.<\/i>, 73, 878\u2013884 (2009)."},{"key":"117","unstructured":"117) Choi DH, Choi JS, Li C, Choi JS. Effects of simvastatin on the pharmacokinetics of diltiazem and its main metabolite, desacetyldiltiazem, after oral and intravenous administration in rats: possible role of P-glycoprotein and CYP3A4 inhibition by simvastatin. Pharmacol. Rep.<\/i>, 63, 1574\u20131582 (2011)."},{"key":"118","unstructured":"118) Tapaninen T, Backman JT, Kurkinen KJ, Neuvonen PJ, Niemi M. Itraconazole, a P-glycoprotein and CYP3A4 inhibitor, markedly raises the plasma concentrations and enhances the renin-inhibiting effect of aliskiren. J. Clin. Pharmacol.<\/i>, 51, 359\u2013367 (2011)."},{"key":"119","unstructured":"119) Sakaeda T, Takara K, Kakumoto M, Ohmoto N, Nakamura T, Iwaki K, Tanigawara Y, Okumura K. Simvastatin and lovastatin, but not pravastatin, interact with MDR1. J. Pharm. Pharmacol.<\/i>, 54, 419\u2013423 (2002)."},{"key":"120","unstructured":"120) Neuvonen PJ, Niemi M, Backman JT. Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance. Clin. Pharmacol. Ther.<\/i>, 80, 565\u2013581 (2006)."},{"key":"121","unstructured":"121) Vigneri R. Diabetes: diabetes therapy and cancer risk. Nat. Rev. Endocrinol.<\/i>, 5, 651\u2013652 (2009)."},{"key":"122","unstructured":"122) Vigneri P, Frasca F, Sciacca L, Pandini G, Vigneri R. Diabetes and cancer. Endocr. Relat. Cancer<\/i>, 16, 1103\u20131123 (2009)."},{"key":"123","doi-asserted-by":"crossref","unstructured":"123) Komura T, Sakai Y, Honda M, Takamura T, Matsushima K, Kaneko S. CD14+ monocytes are vulnerable and functionally impaired under endoplasmic reticulum stress in patients with type 2 diabetes. Diabetes<\/i>, 59, 634\u2013643 (2010).","DOI":"10.2337\/db09-0659"},{"key":"124","unstructured":"124) Kemper EM, Cleypool C, Boogerd W, Beijnen JH, van Tellingen O. The influence of the P-glycoprotein inhibitor zosuquidar trihydrochloride (LY335979) on the brain penetration of paclitaxel in mice. Cancer Chemother. Pharmacol.<\/i>, 53, 173\u2013178 (2004)."},{"key":"125","unstructured":"125) Gallo JM, Li S, Guo P, Reed K, Ma J. The effect of P-glycoprotein on paclitaxel brain and brain tumor distribution in mice. Cancer Res.<\/i>, 63, 5114\u20135117 (2003)."},{"key":"126","unstructured":"126) Lee JH, Lee A, Oh JH, Lee YJ. Comparative pharmacokinetic study of paclitaxel and docetaxel in streptozotocin-induced diabetic rats. Biopharm. Drug Dispos.<\/i>, 33, 474\u2013486 (2012)."},{"key":"127","doi-asserted-by":"crossref","unstructured":"127) Glare P. Choice of opioids and the WHO Ladder. J. Pediatr. Hematol. Oncol.<\/i>, 33 (Suppl. 1), S6\u2013S11 (2011).","DOI":"10.1097\/MPH.0b013e3182121a2b"},{"key":"128","unstructured":"128) Nawa A, Fujita-Hamabe W, Kishioka S, Tokuyama S. Decreased expression of intestinal P-glycoprotein increases the analgesic effects of oral morphine in a streptozotocin-induced diabetic mouse model. Drug Metab. Pharmacokinet.<\/i>, 26, 584\u2013591 (2011)."},{"key":"129","unstructured":"129) Henthorn TK, Liu Y, Mahapatro M, Ng KY. Active transport of fentanyl by the blood\u2013brain barrier. J. Pharmacol. Exp. Ther.<\/i>, 289, 1084\u20131089 (1999)."},{"key":"130","unstructured":"130) Elkiweri IA, Zhang YL, Christians U, Ng KY, Tissot van Patot MC, Henthorn TK. Competitive substrates for P-glycoprotein and organic anion protein transporters differentially reduce blood organ transport of fentanyl and loperamide: pharmacokinetics and pharmacodynamics in Sprague-Dawley rats. Anesth. Analg.<\/i>, 108, 149\u2013159 (2009)."},{"key":"131","unstructured":"131) Hassan HE, Myers AL, Lee IJ, Coop A, Eddington ND. Oxycodone induces overexpression of P-glycoprotein (ABCB1) and affects paclitaxel\u2019s tissue distribution in Sprague Dawley rats. J. Pharm. Sci.<\/i>, 96, 2494\u20132506 (2007)."},{"key":"132","unstructured":"132) Dagenais C, Graff CL, Pollack GM. Variable modulation of opioid brain uptake by P-glycoprotein in mice. Biochem. Pharmacol.<\/i>, 67, 269\u2013276 (2004)."}],"container-title":["Biological and Pharmaceutical Bulletin"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/36\/9\/36_b13-00369\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,16]],"date-time":"2021-03-16T05:23:20Z","timestamp":1615872200000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/36\/9\/36_b13-00369\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013]]},"references-count":132,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2013]]}},"URL":"https:\/\/doi.org\/10.1248\/bpb.b13-00369","relation":{},"ISSN":["0918-6158","1347-5215"],"issn-type":[{"value":"0918-6158","type":"print"},{"value":"1347-5215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013]]}}}